SecBot SecBot
SECBOTREPLAY Home › Report › ERAS

ERAS · Erasca, Inc

Erasca, Inc. · 8-K filed Apr 21, 2026 at 09:10 ET

At the news

BULLISHIMPACT 7/10

8-K filed Apr 21, 2026 at 09:10 ET

Erasca, Inc. updated guidance, narrowing the expected timing for the Phase 1 monotherapy data readout of its pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and JYP0015M101 trials to no later than mid-May 2026, an acceleration from prior 'first half of 2026' guidance. This clinical milestone is critical for validating the drug's efficacy in RAS-mutant solid tumors.

  • Erasca narrowed the anticipated Phase 1 monotherapy data readout for ERAS-0015 to no later than mid-May 2026, up from prior guidance of first half of 2026.
  • Data will come from two trials: AURORAS-1 (Erasca's trial in RAS-mutant solid tumors) and JYP0015M101 (conducted by licensor Joyo in China).
  • ERAS-0015 is a pan-RAS molecular glue, a novel mechanism targeting a key oncogenic pathway with high therapeutic potential.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access